Clinical use of modern fluoroquinolones in dental implantation and maxillary sinus lifting

New fluoroquinolones like levofloxacine, with broad-spectrum of effect which is also active against anaerobic bacteria, is a prospective drug for the prevention of the inflammatory complications in implant dentistry and maxillary sinus augmentation. 34 patients have been selected forthis study, including 16 women and 18 men aged 18 - 65. All the patients have been classified into the main and control groups. Patiens of the first group have been prescribed 500 mg of levofloxacine before and after the operation two times a day for 10 days. Patients of the control group have been treated with amocxicilline. In the control group, which has used amoxicilline, Streptococcus sanguis, Streptococcus salivarius and anaerobic bacteria have been identified. The amount of Prevotella intermedia is insignificant. The same picture has been found with Fusobacterium spp. The rate of Actinomyces spp. was insignificant over the whole period of study. Patients of the experimental group had a slightly different distribution of bacteria. On the 10th day after the operation in the main patient group no periodontal pathogenesis, which may cause inflammatory complications have been identified. During the early post-operative period no significant differences have been observed among the patients of both groups.